NSAIDS
New NSAIDS research from University of Texas discussed
Published in Cardiovascular Business Week, February 5th, 2008
According to a study from the United States, "Concerns of increased cardiovascular (CV) thromboembolic adverse effects from nonsteroidal antinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits. In this descriptive review, we critically examine the randomized, active and placebo-controlled studies, observational trials, and meta-analyses evaluating the CV adverse effects associated with long-term and short-term use of COX-2 selective inhibitors and NS-NSAIDs."
"The potential mechanisms for these CV effects are also presented. Although the studies evaluating the CV...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- Algorithms
Scientists at Medtronic, Inc. discuss research in algorithms - Angiology
ImpactRx Tracks Decline in Zetia and Vytorin Prescribing - Anxiety Disorders
Prescription 'Mind Meds' Pose Dangerous Threat to College Students - Aortic Dissection
Cook Medical Begins Patient Enrollment in STABLE Aortic Dissection Trial - Artificial Organs
Abiomed Receives HDE Supplement Approval for AbioCor(R) Artificial Heart - Association of Black Cardiologists
African Americans Should Not Stop Taking Vytorin or Zetia Without Consulting Their Healthcare Providers - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
